CME Group (NASDAQ: CME) Posts Record Q1 Revenue and Net Income on 22% ADV Surge

NASDAQ: CME · April 22, 2026 · 3 min read

CME Group Inc. (NASDAQ: CME) shares edged up $1.31 (0.46%) to $285.71 after the exchange operator disclosed record first-quarter revenue and net income in an 8-K filing dated April 22, 2026 (Results of Operations, Item 9.01). The headline performance was underpinned by a 22% year-over-year increase in average daily volume across all asset classes, alongside expanded participation from non-U.S. clients — even as reported earnings per share and revenue came in below Wall Street estimates.

Q1 2026 At a Glance

• Average daily volume rose 22% year-over-year across all asset classes
• Revenue and net income both reached all-time quarterly highs
• EPS and revenue missed analyst consensus estimates for the period
• Non-U.S. client participation increased, broadening the revenue base
• New derivatives tools introduced: options on Eris SOFR Swap futures and updated Equity Index Dividend products
• Trailing P/E stands at 25.6x; forward P/E at 22.1x
• Net margin: 62.6% | Operating margin: 63.8% | Revenue growth (YoY): 8.0% | Earnings growth (YoY): 35.0%

What Drove the Results

The 22% rise in average daily volume reflects elevated client activity across interest rates, equities, energy, and agricultural futures — markets that have seen heightened price volatility in recent months. Commodity markets, in particular, remained active: WTI Crude Oil futures held above $90 per barrel amid Strait of Hormuz disruptions, while grain markets processed competing signals from global headlines and domestic planting data.

On the product side, CME Group broadened its derivatives toolkit, launching options on Eris SOFR Swap futures and refreshing its Equity Index Dividend product suite. These additions are consistent with the company's ongoing strategy of deepening its rate and equity derivatives franchise. The combination of strong volume and disciplined cost management is reflected in the company's 63.8% operating margin and 35.0% earnings growth year-over-year.

Wall Street View

Analyst sentiment on CME Group remains broadly constructive, though the distribution has shifted slightly. As of April 2026, the consensus stood at 2 Strong Buy, 8 Buy, 7 Hold, 3 Sell, and 0 Strong Sell. Compared to the prior month — which showed 3 Strong Buy, 8 Buy, and 6 Hold — the shift reflects a modest softening at the top of the conviction spectrum, alongside a small increase in Sell ratings, possibly tied to the Q1 estimate misses.

Investor Takeaway

Despite the earnings and revenue miss relative to estimates, CME Group's record top- and bottom-line results, paired with 22% volume growth and industry-leading margins, underscore the durability of its exchange model. The forward P/E of 22.1x represents a modest compression from the trailing multiple of 25.6x, suggesting the market is pricing in continued earnings expansion. Analyst consensus remains tilted toward Buy, though the slight drift in ratings warrants monitoring as full Q1 details are absorbed.